IP Library › Granted Patent US 12,344,608
Granted Patent B2
US 12,344,608 · App. 18/750,829 · Granted Jul 1, 2025

Positive modulators of the muscarinic acetylcholine receptor M4

Inventors: Craig W. Lindsley (Brentwood, TN); Darren W. Engers (Brentwood, TN); Kayla J. Temple (Spring Hill, TN); Alison R. Gregro (Mount Juliet, TN); Alexa E. Richardson (Nashville, TN); Madeline F. Long (Nashville, TN)
Assignee: Vanderbilt University
C07D471/04A61K31/4545C07B59/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,608
App. No.
18/750,829
Granted
Jul 1, 2025
Kind
B2
Abstract

Deuterium-labeled 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidines substituted with pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one are positive allosteric modulators of the muscarinic acetylcholine receptor M 4 (mAChR M 4 ) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.

Claims (8)

1. A compound

or a pharmaceutically acceptable salt thereof, that has at least 25% deuterium incorporation at each deuterium label.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, that has at least 50% deuterium incorporation at each deuterium label.

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, that has at least 75% deuterium incorporation at each deuterium label.

4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, that has at least 90% deuterium incorporation at each deuterium label.

5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, that has at least 99.5% deuterium incorporation at each deuterium label.

6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, that has at least 99.9% deuterium incorporation at each deuterium label.

7. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2024
From: LINDSLEY, CRAIG W.; ENGERS, DARREN W.; TEMPLE, KAYLA J.; GREGRO, ALISON R.; RICHARDSON, ALEXA E.; LONG, MADELINE F.
To: VANDERBILT UNIVERSITY
Reel/Frame 068219/0169 →
Continuity (3)
Provisional Application 63610220 · Dec 14, 2023
Provisional Application 63509589 · Jun 22, 2023
Related Publication 20250011320A1 · Jan 9, 2025
References Cited (33)
US 10329289B2 · Bao et al. · 2019 [cited by applicant]
US 11884676B2 · Lindsley et al. · 2024 [cited by applicant]
WO 2017112719A1 · 2017 [cited by applicant]
WO WO2017107087A1 · 2017 [cited by examiner]
WO 2018112840A1 · 2018 [cited by applicant]
WO 2018118736A1 · 2018 [cited by applicant]
WO WO2022015988A1 · 2022 [cited by examiner]
Harbeson, S. L., et al., Deuterium in Drug Discovery and Development, Annual Reports in Medicinal Chemistry, vol. 46, Chapter 24, 2011, 404-415. (Year: 2011). [cited by examiner]
1,2-DIBROMOETHANE-D4 (D, 99%). Safety Data Sheet. Cambridge Isotope Laboratories, Inc. pp. 1-10. (Year: 2017). [cited by examiner]
Spock, M., et al. ACS Med. Chem. Lett. 2021, 12, 1342-1349. (Year: 2021). [cited by examiner]
U.S. Appl. No. 19/002,083, filed Dec. 26, 2024, Lindsley C. [cited by examiner]
U.S. Appl. No. 19/002,103, filed Dec. 26, 2024, Lindsley C. [cited by examiner]
U.S. Appl. No. 19/002,334, filed Dec. 26, 2024, Lindsley C. [cited by examiner]
U.S. Appl. No. 19/002,355, filed Dec. 26, 2024, Lindsley C. [cited by examiner]
Gleason, J. D., and Friedman, I. Science. 1970, 169, 1085-1086. (Year: 1970). [cited by examiner]
Bodick, N. C., et al. “Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.” Archives of neurology 54.4 (1997): 465-473. [cited by applicant]
Bubser, M., et al. “Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.” ACS chemical neuroscience 5.10 (2014): 920-… [cited by applicant]
Bymaster, F. P., et al. “Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R, 6R) 6-(3-propylthio-1, 2, 5-thiadiazol-4-yl)-1-azabicyclo [3.2. 1] octane.” European journal of pharmacology 356.2… [cited by applicant]
Bymaster, F. P., et al. “Potential role of muscarinic receptors in schizophrenia.” Life sciences 64.6-7 (1999): 527-534. [cited by applicant]
Conde-Ceide, S., et al. “Discovery of VU0409551/JNJ-46778212: an mGlu5 positive allosteric modulator clinical candidate targeting schizophrenia.” ACS medicinal chemistry letters 6.6 (2015): 716-720. [cited by applicant]
Felts, A. S., et al. “Discovery of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy) picolinamide (VU0424238): a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinic… [cited by applicant]
Garrison, A. T., et al. “Development of VU6019650: a potent, highly selective, and systemically active orthosteric antagonist of the M5 muscarinic acetylcholine receptor for the treatment of opioid use disorder.” Journa… [cited by applicant]
Johnson, C. R., et al. “Drug design targeting the muscarinic receptors and the implications in central nervous system disorders.” Biomedicines 10.2 (2022): 398. [cited by applicant]
Morris, L. C., et al. “Discovery of (S)-2-Cyclopentyl-N-((1-Isopropylpyrrolidin2-Yl)-9-Methyl-1-Oxo-2, 9-Dihydro-1 H-Pyrrido [3, 4-b] Indole-4-Carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 rece… [cited by applicant]
Shannon, H. E., et al. “Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.” Journal of Pharmacology and Experimental Therapeutics 290.2 (1999)… [cited by applicant]
Shannon, H. E., et al. “Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.” Schizophrenia research 42.3 (2000): 249-259. [cited by applicant]
Stanhope, K. J., et al. “The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.” Journal of Pharmacology and Experimental Therapeutics 299.2 (2001): 782-792. [cited by applicant]
Yu, W., et al. “Discovery of ethyl ketone-based highly selective HDACs 1, 2, 3 inhibitors for HIV latency reactivation with minimum cellular potency serum shift and reduced hERG activity.” Journal of Medicinal Chemistry… [cited by applicant]
Ao et al., “Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK),” Journal of Labelled Compound… [cited by applicant]
CAS No. 22581-63-1, “1,2-Dibromoethane-d4,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/aldrich/425362>, 9 pages. [cited by applicant]
CAS No. 530-62-1, “1,1′-Carbonyldiimidazole,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/mm/802301>, 9 pages. [cited by applicant]
CAS No. 937-14-4, “3-Chloroperbenzoic acid,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/aldrich/273031>, 12 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2024/035078, mailed on Oct. 8, 2024, 12 pages. [cited by applicant]